Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
COCP | US
-0.16
-7.27%
Healthcare
Biotechnology
30/06/2024
17/10/2024
2.04
2.19
2.45
1.87
Cocrystal Pharma Inc. a biotechnology company focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV) influenza virus coronavirus and norovirus infections. The company develops CC-31244 a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344 a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell Washington.
View LessPositive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Weakness based on declining price with high volume
High Short-term Volatility
High 6-Month Volatility (>65%)
High Current Volume and Negative 1-Day Return
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
117.0%1 month
83.5%3 months
81.9%6 months
77.4%-
-
1.02
0.10
0.08
0.66
17.89
-
-21.15M
20.75M
20.75M
-
-
-
26.90
-68.86
4.69
0.77
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.75
Range1M
0.85
Range3M
0.85
Rel. volume
4.05
Price X volume
161.85K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Cyclo Therapeutics Inc | CYTH | Biotechnology | 0.7849 | 22.52M | -0.65% | n/a | -58.50% |
Pieris Pharmaceuticals Inc | PIRS | Biotechnology | 16.93 | 22.08M | 2.67% | n/a | 0.00% |
NeuroSense Therapeutics Ltd. Ordinary Shares | NRSN | Biotechnology | 1.1 | 21.79M | 12.30% | n/a | -2.11% |
HCW Biologics Inc. Common Stock | HCWB | Biotechnology | 0.56 | 21.18M | -6.67% | n/a | -159.13% |
Spruce Biosciences Inc | SPRB | Biotechnology | 0.51 | 21.06M | -1.75% | n/a | 6.24% |
Matinas BioPharma Holdings Inc | MTNB | Biotechnology | 4.08 | 20.66M | 4.88% | n/a | 16.97% |
BIOR | BIOR | Biotechnology | 0.5538 | 20.20M | -6.14% | n/a | -52.57% |
MONOPAR THERAPEUTICS | MNPR | Biotechnology | 5.71 | 20.10M | 8.56% | n/a | 0.00% |
Klotho Neurosciences Inc. | KLTO | Biotechnology | 0.59 | 20.06M | 5.06% | n/a | 0.00% |
Cadrenal Therapeutics Inc. Common Stock | CVKD | Biotechnology | 16.3 | 19.27M | 6.19% | n/a | 0.22% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.6 | 19.19M | 0.80% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 0.98 | 17.70M | -3.92% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.66 | 0.53 | Expensive |
Ent. to Revenue | 17.89 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 1.02 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 81.89 | 72.92 | Par |
Debt to Equity | 0.10 | -1.24 | Expensive |
Debt to Assets | 0.08 | 0.25 | Cheaper |
Market Cap | 20.75M | 3.78B | Emerging |